Prostaglandin E2 (PGE2) molecule and its receptors play an important role in the development of malignancies and metastases therefore PGE2 may play a crucial role in the diagnosis and a new therapeutic target in the field of radionuclide therapy of PGE2-positive tumors. PGE2 form complexes with RAMEB (randomly-methylated-beta-cyclodextrin) with high affinity therefore the aim of this present study was to synthesize a PGE2-specific DOTAGA-RAMEB, which can be labeled with diagnostic and therapeutic isotopes also and binds to PGE2-positive tumors. DOTAGA-RAMEB was labeled with 68 Ga and 205/206 Bi radionuclides and their radiochemical purity (RCP%), partition coefficient (log P values), and in vitro and in vivo stability were determined. For the assessment of the biological properties and the PGE2 specificity of [ 68 Ga]Ga-DOTAGA-RAMEB and [ 205/206 Bi]Bi-DOTAGA-RAMEB in vivo PET imaging and ex vivo biodistribution studies were performed using healthy control and PGE2-positive BxPC-3 tumor-bearing CB17 SCID mice. The RCP% of the newly synthesized [ 68 Ga]Ga-DOTAGA-RAMEB and [ 205/206 Bi]Bi-DOTAGA-RAMEB was higher than 98 %. In vivo studies showed that the tumor-to-background ratio of [ 68 Ga]Ga-DOTAGA-RAMEB was 2.5 ± 0.2 as a result BxPC-3 tumors were clearly identified on PET images. Beside this the ex vivo biodistribution studies showed that the accumulation rate of [ 68 Ga]Ga-DOTAGA-RAMEB and [ 205/206 Bi]Bi-DOTAGA-RAMEB was similar in the PGE2-positive BxPC-3 tumors.
No takes yet. Share an insight, caveat, or question.
Csige et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: